Human epidermal growth factor receptor 2 (HER2) is associated with high-grade breast cancer and a high risk of recurrence; its assessment is important for targeting therapy with monoclonal antibody (trastuzumab) against HER2. The gene discussed is ERBB2; the disease is breast cancer.